Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.04%
As of Thursday, September 24, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.26%
As of Wednesday, September 23, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.15%
As of Tuesday, September 15, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Michael Rose
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 5.05%
As of Thursday, September 10, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Michael Rose
Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Down 9.03%
As of Monday, August 31, Tectonic Therapeutic, Inc.’s TECX share price has dipped by 9.03%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TECX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $385.8 | $226.9 | 35% |
|
| Shares Out (Mil) | 19.0 | 53.4 | 30% |
|
| Institutional Ownership | 67.7% | 92.9% | 42% |
|
| Float (Mil) | 11.9 | 40.7 | 22% |
|
| Beta | 0.22 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 178 | 469 | 44% |
|
| Price Change (52-week) |
6.0% | 46.6% | 57% |
|
| Growth | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TECX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($44) | 12% |
|
| EPS (TTM) | ($4.564) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($72) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($60) | $2 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $383 | $174 | 32% |
|
| Valuation | TECX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.70 | 2.17 | 47% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TECX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.6% | na |
|
| Net Margin | na | (71.5%) | na |
|
| ROA | (32.2%) | (47.1%) | 16% |
|
| ROE | (33.8%) | (53.0%) | 19% |
|
| Liabilities to Assets | 5.6% | 29.6% | 3% |
|
| F-Score | 1 | 2 | 1% |
|
Tectonic Therapeutic, Inc. did not pass any screens on 10/30/2026.
